Advancements in chemotherapy and immunotherapy have improved multiple myeloma survival rates, with 5-year relative survival increasing from 37.7% to 60.3% between 2000-2004 and 2015-2019. Treatment ...

Teclistamab improved PFS, OS in patients who had received up to three previous lines of th ...

BVd regimen showed significant OS improvement over DVd in relapsed/refractory multiple myeloma, with a predicted median OS of 84 months versus 51 months. BVd achieved higher ORR (83.1% vs 71.3%) and ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

Patients with newly diagnosed multiple myeloma (NDMM) treated at a specialized clinic have improved outcomes, with median overall survival (OS) of 152 months, according to a research letter published ...

-- Company to host a live webcast event with an expert panel of clinicians during ASH -- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell ...

BMS Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care ...

RALEIGH, N.C. (WTVD) -- The American Cancer Society reports that the five-year relative cancer survival rate for all cancers combined hit 70% for people diagnosed between 2016-2021 in the United ...